Chemoinformaics analysis of  Cyclovirobuxine-D
| Molecular Weight | 402.667 | nRot | 3 |
| Heavy Atom Molecular Weight | 356.299 | nRig | 22 |
| Exact Molecular Weight | 402.361 | nRing | 5 |
| Solubility: LogS | -2.699 | nHRing | 0 |
| Solubility: LogP | 3.903 | No. of Aliphatic Rings | 5 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 2 | No. of Aliphatic Carbocycles Rings | 5 |
| Atoms Count | 75 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 29 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 5 |
| No. of Hydrogen atom | 46 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 26 | No. of Saturated Rings | 5 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 3 | APOL | 77.0945 |
| nHD | 3 | BPOL | 47.2875 |
| QED | 0.647 |
| Synth | 5.757 |
| Natural Product Likeliness | 3.117 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.009 |
| Pgp-sub | 0.001 |
| HIA | 0.32 |
| CACO-2 | -5.31 |
| MDCK | 0.00000966 |
| BBB | 0.151 |
| PPB | 0.537434 |
| VDSS | 0.717 |
| FU | 0.493597 |
| CYP1A2-inh | 0.007 |
| CYP1A2-sub | 0.282 |
| CYP2c19-inh | 0.027 |
| CYP2c19-sub | 0.954 |
| CYP2c9-inh | 0.038 |
| CYP2c9-sub | 0.101 |
| CYP2d6-inh | 0.353 |
| CYP2d6-sub | 0.901 |
| CYP3a4-inh | 0.624 |
| CYP3a4-sub | 0.779 |
| CL | 9.274 |
| T12 | 0.023 |
| hERG | 0.083 |
| Ames | 0.012 |
| ROA | 0.298 |
| SkinSen | 0.215 |
| Carcinogencity | 0.021 |
| EI | 0.003 |
| Respiratory | 0.969 |
| NR-Aromatase | 0.003 |
| Antiviral | No |
| Prediction | 0.701679 |